Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022Show others and affiliations
2022 (English)In: Eurosurveillance, ISSN 1025-496X, E-ISSN 1560-7917, Vol. 27, no 24
Article in journal (Refereed) Published
Abstract [en]
We describe a gonorrhoea case with ceftriaxone plus high-level azithromycin resistance. In April 2022, an Austrian heterosexual male was diagnosed with gonorrhoea after sexual intercourse with a female sex worker in Cambodia. Recommended treatment with ceftriaxone (1 g) plus azithromycin (1.5 g) possibly failed. Worryingly, this is the second strain in an Asian Neisseria gonorrhoeae genomic sublineage including high-level azithromycin-resistant strains that developed ceftriaxone resistance by acquisition of mosaic penA-60.001. Enhanced resistance surveillance and actions are imperative to prevent spread.
Place, publisher, year, edition, pages
European Centre for Disease Prevention and Control , 2022. Vol. 27, no 24
Keywords [en]
Neisseria gonorrhoeae, XDR, ceftriaxone resistance, extensively drug-resistant, high-level azithromycin resistance
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-99649DOI: 10.2807/1560-7917.ES.2022.27.24.2200455ISI: 000815142300003PubMedID: 35713023Scopus ID: 2-s2.0-85132285154OAI: oai:DiVA.org:oru-99649DiVA, id: diva2:1673017
Note
Funding agencies:
Örebro County Council Research Committee
Foundation for Medical Research at Örebro University Hospital, Sweden
2022-06-202022-06-202022-09-15Bibliographically approved